Month: July 2020

AMSTERDAM, July 08, 2020 (GLOBE NEWSWIRE) — TomTom (TOM2), the location technology specialist, today announced an extension of its global deal to provide maps and traffic data to Michelin Travel Partner. TomTom will continue to power ViaMichelin, Michelin Travel Partner’s world-renowned digital travel service, and several of the brand’s printed products, including travel guides.ViaMichelin is a mobile app and web-based platform which provides online mapping, navigation, road traffic services and tourist information. TomTom’s maps and real-time traffic service provide highly detailed location content, critical to location-aware digital applications like ViaMichelin.“We are pleased to extend our collaboration with Michelin Travel Partner and continue to support ViaMichelin’s one hundred million users worldwide,” said Anders Truelsen,...

WISeKey IoT Cybersecurity Allows Electric Vehicles to Securely Communicate with Charging Stations and Network of VehiclesGENEVA – July 8, 2020 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN / Nasdaq: WKEY), a leading Swiss cybersecurity and IoT company today announced that is combining software and microchips to allow Electric Vehicles (EVs) to securely communicate with charging stations, the network of connected vehicles, and even the electrical grid.The company has shown strong growth and made tremendous progress on the EV and Connected Vehicle industry with the signing of strategic partnerships with leading European automobile manufacturers.   WISeKey’s initial application was based on the integration of the WISeKey IoT and Public Key Infrastructure (PKI) in the manufacturers connected car solutions which allowed them...

Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 antibody Sarclisa® enables optimal tumor cell killing, and offers a potential first-in-class treatment for patients with multiple myelomaKiadis receives €17.5 million up front payment; potential for up to €857.5 million in preclinical, clinical, regulatory and commercial milestone payments, and up to double-digit royaltiesKiadis to hold conference call with investors and analysts at 16:00 CET todayAmsterdam, The Netherlands, July 8, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative natural killer cell therapies for patients with life-threatening diseases, today announces the exclusive license of Kiadis’ previously undisclosed K-NK004 program to Sanofi. The...

SalMar’s subsidiary Ocean Farming AS has been granted its eight development licenses converted into ordinary fish production licenses. The Norwegian Directorate of Fisheries informed the company of its decision in a letter dated 7th of July 2020.This means that the eight licenses the company was granted on 26 February 2016 for the realization of its offshore fish farming facility (Ocean Farm 1) can now be included in its ordinary production, within the framework and regulations governing maximum allowable biomass (MAB).In its decision, the Directorate of Fisheries points out that Ocean Farming has provided comprehensive and thourough documentation showing that the performance criteria and thus the conditions for conversion have been fulfilled. The experience gained through the project has been described and reported to the Directorate...

SalMars datterselskap Ocean Farming AS har fått konvertert sine åtte utviklingstillatelser til ordinære tillatelser for matfiskproduksjon. Dette kommer frem av brev 7.7.2020 fra Fiskeridirektoratet.Dette betyr at de åtte tillatelsene selskapet 26.2.2016 fikk tilsagn om for realisering av sin «havmerd» (Ocean farm 1) nå kan inngå i selskapets ordinære produksjon innenfor rammen og reglene for maksimal tillatt biomasse (MTB).Fiskeridirektoratet påpeker i sitt vedtak at Ocean Farming har levert fyldig og god dokumentasjon som viser at målkriteriene og dermed vilkårene for konvertering er oppfylt. Erfaringene som er høstet fra prosjektet er beskrevet og innrapportert til Fiskeridirektoratet, senest i form av en sluttrapport og en egen rapport om utviklingen av prosjektet første halvår 2020. Rapportene er offentlig tilgjengelig. På den måten...

SEATTLE, July 08, 2020 (GLOBE NEWSWIRE) — SAFR® from RealNetworks, Inc. (NASDAQ: RNWK), the world’s premier facial recognition and computer vision platform for live video, today announced the addition of Walter Candelu as Area Vice President for the Middle East. Mr. Candelu brings experience and leadership to the new SAFR office in Dubai. He will drive its growing sales and business development initiatives across the Middle East Region. Mr. Candelu will be based in Dubai, UAE and will focus on expanding the SAFR reseller channel, partner network, and regional sales and marketing programs. Prior to joining SAFR, he held senior positions with leading security companies where he successfully drove the exponential growth of their technical capabilities and revenue. Most recently he was the Head of Sales and Business Development for...

NORTHBROOK, Ill., July 07, 2020 (GLOBE NEWSWIRE) — The Allstate Corporation (NYSE: ALL) has agreed to acquire National General Holdings Corporation for approximately $4 billion in cash, or $34.50 per share. The transaction is expected to close in early 2021, subject to regulatory approvals and other customary closing conditions.“Acquiring National General accelerates Allstate’s strategy to increase market share in personal property-liability and significantly expands our independent agent distribution,” said Tom Wilson, Chair, President and CEO. “The acquisition increases personal lines premiums by $4.0 billion and market share by over 1 percentage point to 10%. National General’s business and technology platforms will be utilized to further strengthen Allstate’s existing independent agent businesses. The transaction will be accretive...

SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the pricing of its previously announced underwritten public offering of 7,142,857 shares of its common stock at a price to the public of $42.00 per share. The gross proceeds to Vir from the offering before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $300.0 million. The offering is expected to close on July 10, 2020, subject to satisfaction of customary closing conditions. In addition, Vir has granted the underwriters a 30-day option to purchase up to 1,071,428 additional shares of its common stock.Goldman Sachs & Co. LLC, BofA Securities, Cowen and Barclays...

COPENHAGEN, Denmark, July 07, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $142.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about July 10, 2020 subject to customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 633,802 ADSs at the public offering price, less the underwriting commissions.Ascendis estimates net proceeds from the offering to be approximately $569.2 million (assuming no exercise...

SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized underwritten public offering of 2,649,600 shares of its common stock at a public offering price of $27.50 per share. The gross proceeds of the offering, before deducting the underwriting discount and other offering expenses payable by 89bio, are expected to be approximately $72.9 million. All of the shares are being offered by 89bio.  In addition, 89bio has granted the underwriters a 30-day option to purchase up to an additional 397,440 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering...